FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Triamcinolone Acetonide (Triesence) Injection, Suspension
Status: Currently in Shortage
»Date first posted: 09/12/2019
»Therapeutic Categories: Ophthalmology

Novartis (New 09/12/2019)

Company Contact Information:
888-669-6682

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
Triesence (Triamcinolone acetonide injectable suspension) Vial 40mg/mL 1mL in 1 vial (NDC 0065-0534-01) Unavailable. Estimated Shortage Duration: November 2019 Requirements related to complying with good manufacturing practices

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English